Development and validation of the CAIL prognostic score in non‐small cell lung cancer patients with malignant pleural effusion
The Clinical Respiratory Journal · 2023-11 · 17 (11) · 1158-1168
DOI: 10.1111/crj.13700 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 18.09.2023. Verfasst von Tianyuan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, 1-3-5 project for disciplines of excellence, West China Hospital, Sichuan University, China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with malignant pleural effusion (MPE) typically have poor prognoses, and predicting survival is challenging. The present study aimed to identify prognostic factors of overall survival (OS) in non‐small cell lung cancer (NSCLC) patients with MPE in the time of immunotherapy and targeted therapy.
Methods
Data of 344 consecutive NSCLC patients with MPE on clinical, radiological, and molecular characteristics and treatment options were collected. The risk factors in the training cohort were assessed using univariate and multivariate proportional hazards analyses. A clinical prognostic score was established and validated.
Results
According to the results of the multivariable survival analysis, the Eastern C ooperative Oncology Group (ECOG) performance score (PS), a ntiangiogenic therapy, i mmunotherapy, and l actic dehydrogenase (LDH) in pleural fluid (CAIL) prognostic score was developed ( n = 275) and subsequently validated ( n = 69). Patients who underwent risk stratification into low‐, moderate‐, and high‐risk groups had median OS of 46.1, 23.1, and 9.6 months, respectively ( P < 0.0001). The area under the curve (AUC) analysis showed the CAIL score to be superior at predicting survival compared with the LENT score at 6 (0.84 vs. 0.77, P < 0.01), 12 (0.87 vs. 0.82, P < 0.01), and 36 months (0.80 vs. 0.77, P < 0.01).
Conclusions
For NSCLC patients with MPE, the validated CAIL prognostic score integrates clinical characteristics and therapeutic modalities to predict survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu,…
- Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Panwen Tian, Yalun Li
Förderung
- National Natural Science Foundation of China
- 1-3-5 project for disciplines of excellence
- West China Hospital, Sichuan University, China
- West China Hospital, Sichuan University
Zitieren
APA
Li, T., Tian, P., Huang, Q., Zeng, H., Wei, Q., & Li, Y. (2023). Development and validation of the CAIL prognostic score in non‐small cell lung cancer patients with malignant pleural effusion. The Clinical Respiratory Journal, 17(11), 1158-1168. https://doi.org/10.1111/crj.13700
Vancouver
Li T, Tian P, Huang Q, Zeng H, Wei Q, Li Y. Development and validation of the CAIL prognostic score in non‐small cell lung cancer patients with malignant pleural effusion. The Clinical Respiratory Journal. 2023;17(11):1158-1168. doi:10.1111/crj.13700
BibTeX
@article{Li2023,
author = {Li, Tianyuan and Tian, Panwen and Huang, Qin and Zeng, Hao and Wei, Qi and Li, Yalun},
title = {Development and validation of the CAIL prognostic score in non‐small cell lung cancer patients with malignant pleural effusion},
journal = {The Clinical Respiratory Journal},
year = {2023},
volume = {17},
number = {11},
pages = {1158--1168},
doi = {10.1111/crj.13700}
}
EUVIMED